secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2026-06-30T21:19:32+00:00
Accession:  0001493152-26-031328
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma shareholders approve reverse stock split and equity plan amendments
--------------------------------------------------------------------------------

- Stockholders approved reverse stock split at ratio between 1:3 and 1:250, with board discretion on timing.
- Amendment to certificate of incorporation passed with 11,232,321 for, 1,945,235 against, 272,950 abstain.
- Equity incentive plan increased by 5M shares plus 5% annual evergreen for 10 years; approved with 7,067,866 for.
- All four director nominees elected; auditor Weinberg & Company ratified; advisory executive compensation approved.
- Annual meeting had 62.81% voter turnout; 13,450,506 shares voted out of 21,411,198 eligible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226031328/0001493152-26-031328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226031328/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-031328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer